Cannabinoid hyperemesis syndrome is increasingly important as cannabis use grows and THC potency rises

A Federal Practitioner review highlighted that converging factors of cannabis legalization, increasing use, and rising THC potency make cannabinoid hyperemesis syndrome an increasingly important condition for clinicians to recognize.

Fleming, J Eric et al.·Federal practitioner : for the health care professionals of the VA·2017·Preliminary EvidenceReview
RTHC-01380ReviewPreliminary Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

The review from a federal healthcare publication emphasized that cannabinoid hyperemesis syndrome (CHS) sits at the intersection of three converging trends: legislative efforts expanding cannabis access, increasing prevalence of cannabis use, and rising THC potency. These factors combine to make CHS a more commonly encountered but still frequently missed diagnosis.

Key Numbers

The review highlights three converging factors: legislative changes, increasing prevalence, and THC toxicity.

How They Did This

Clinical review article published in a federal healthcare practitioner journal aimed at VA, DoD, and PHS healthcare professionals.

Why This Research Matters

CHS is often misdiagnosed or unrecognized, leading to repeated ER visits, unnecessary testing, and delayed treatment. Healthcare providers in federal settings (VA, military, public health) need awareness as cannabis use patterns evolve among their patient populations.

The Bigger Picture

The publication venue, Federal Practitioner (serving VA, DoD, and PHS), is notable. Federal healthcare systems serve populations with distinct cannabis use patterns, and clinician education in these settings is essential for recognizing CHS.

What This Study Doesn't Tell Us

Brief overview article with a very concise abstract. Limited detail on specific clinical recommendations or evidence base.

Questions This Raises

  • ?How common is CHS in federal healthcare patient populations?
  • ?Are VA and military healthcare providers adequately trained to recognize CHS?
  • ?Does the federal scheduling of cannabis affect CHS reporting and diagnosis?

Trust & Context

Key Stat:
Converging factors: legalization + increased use + higher THC potency = more CHS cases
Evidence Grade:
Brief clinical overview. Provides awareness but limited detailed evidence review.
Study Age:
Published in 2017. CHS awareness in clinical practice has continued to improve.
Original Title:
Cannabinoid Hyperemesis Syndrome.
Published In:
Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 34(10), 33-36 (2017)
Database ID:
RTHC-01380

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What is cannabinoid hyperemesis syndrome?

CHS is a condition where chronic cannabis users develop recurrent episodes of severe nausea, vomiting, and abdominal pain. It is paradoxical because cannabis is often used to treat nausea. Symptoms resolve completely when cannabis use stops.

Why is CHS becoming more common?

Three factors are converging: more states legalizing cannabis, more people using it, and cannabis products becoming more potent (higher THC). Higher THC exposure may increase the likelihood of developing CHS.

Read More on RethinkTHC

Cite This Study

RTHC-01380·https://rethinkthc.com/research/RTHC-01380

APA

Fleming, J Eric; Lockwood, Sean. (2017). Cannabinoid Hyperemesis Syndrome.. Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 34(10), 33-36.

MLA

Fleming, J Eric, et al. "Cannabinoid Hyperemesis Syndrome.." Federal practitioner : for the health care professionals of the VA, 2017.

RethinkTHC

RethinkTHC Research Database. "Cannabinoid Hyperemesis Syndrome." RTHC-01380. Retrieved from https://rethinkthc.com/research/fleming-2017-cannabinoid-hyperemesis-syndrome

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.